What happened before the Big Bang? And what happened before that? Stephen Hawking’s answer—there was no beginning—is now the subject of intense debate.
A recent challenge to Stephen Hawking’s biggest idea — about how the universe might have come from nothing — has cosmologists choosing sides.
By comparison, the next biggest market, Japan, will be responsible for 11% of all shipments over that same period and the U.S. for 7%. Developing-world markets Mexico, India, Thailand, Vietnam and Brazil will collectively buy just 5% of industrial robots.
China is setting the pace in automation to create the factory of the future.
Since aging is a key driver of many diseases, targeting that process could be a handy catch-all for treating a range of diseases and improving quality of life for pretty much everybody. Researchers at EPFL have now reported a new step towards that goal, with human clinical trials of a fruit-derived compound showing promise in slowing mitochondrial aging in elderly patients, with no side effects found.
The Automobile Club de l’Ouest has announced a new top class for the Le Mans endurance race – a “hypercar” class that will begin in 2020–21, designed to entice some of the world’s most extreme streetcars to throw down and prove themselves. And one we’ll definitely see on track is the awesome Aston Martin Valkyrie.
People like Jo Cameron, who can’t feel any pain, could help us find the on-off switch for suffering.
On the cusp of the 50th anniversary of the Apollo 11 lunar landing, the technological history surrounding this one giant leap is full of surprises.
Scientists found 200 E. coli strains, about half of which were resistant to at least one microbial agent, in manure, air, and horse nostrils at Polish riding centers. Here’s what that means for you.
GSK forms CRISPR alliance with UC Berkeley and UCSF to create functional genomics insitute. The main one, technologywise, is this about using CRISPR as a gene function screen. One can do a gazillion experiments at once, fleshing out connections, sketching the biology, finding drug targets. http://bit.do/eU942
S AN FRANCISCO — The drug maker GlaxoSmithKline announced Thursday that it would team up with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new medicines, establishing a new lab in San Francisco and spending up to $67 million over five years.
Jennifer Doudna, the University of California, Berkeley, researcher who co-invented the CRISPR enzyme technology, will help lead the effort, along with Jonathan Weissman, a UC San Francisco researcher who has been using CRISPR to understand the function of individual human genes and how they work together. Both are Howard Hughes Medical Institute investigators.
The lab will be called the Laboratory for Genomic Research and will be based near UCSF’s Mission Bay campus. The money will fund 24 full-time University of California employees, in addition to as many as 14 full-time GSK employees. GSK’s machine learning and artificial intelligence groups will create computer systems that can handle the large amounts of data the project is expected to create. It will focus on immunology, oncology, and neurology.
Aubrey de Grey, Ph.D., Chief Science Officer and Co-founder of SENS Research Foundation, delivers an overview of aging and the many health problems that develop in our advanced years.
Dr. de Grey is a respected member of the science community; he is the noted biomedical gerontologist who devised the innovative SENS platform and co-founded the SENS Research Foundation to further it. Dr. de Grey has written about his work and as an established researcher, he has been appointed to the editorial and scientific advisory boards of many journals, organizations, etc. Dr. de Grey is a Fellow of the Gerontological Society of America as well as the American Aging Association. He holds a BA in Computer Science and a Ph.D. in Biology from the prestigious University of Cambridge.
Dr. de Grey discusses his research in aging and the motivations for tackling the career. As he states, aging is the number one medical problem as it causes more suffering. He was motivated to research in this area because he found that not enough was being done to focus on aging and the myriad of problems that come with it. He talks about the many excuses that are given as reasons to simply accept aging as it is, or not focus on it at all, such as “it’s inevitable…everything ages,” or the philosophical—“death gives meaning to life,” or social—“maybe we could do this, but it would create new problems worse than the problem we are solving.” And as the Ph.D. states, none of these excuses stand up to even the faintest scrutiny, however, they still remain quite popular.
